Stock screenerAll disclosures →
EDGAR →
QURE
Conviction 51HealthcareScan · Thu, Sep 24, 2026uniQure N.V. (QURE) closed at $38.32 (-10.40%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 31, RS Rating 98, -45.7% from its 52-week high, +63.8% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
QURE$38.32-10.40%
ResistanceSupportVol 14Insider sell3
Vol MA14 1.57M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price38.32
Change-10.40%
Gap-0.37%
Rel volume5.48×
Avg volume1.49M
Avg $ vol65.04M
SMA 2045.02
SMA 5044.51
SMA 20029.47
Price vs 50-13.93%
Price vs 200+30.00%
MA stackmixed
50/200 cross—
Supertrenddown · 46.90
RSI (14)31
MACD hist-0.62
MACD cross—
Stoch %K / %D15 / 25
ADX (14)18
+DI / −DI18 / 37
RSI divergence—
MACD divergence—
ATR %5.98%
ADR %4.76%
52w high70.59
52w low9.03
From 52w high-45.72%
Above 52w low+324.31%
New 52w highNo
SqueezeOff
Bollinger width21.96%
%B-0.18
Donchian pos10.46%
Donchian high51.03
Donchian low36.83
AVWAP (52w high)27.49
vs AVWAP high+39.40%
AVWAP (52w low)29.51
vs AVWAP low+29.85%
OBV trendDown
Chaikin MF (20)-0.25
Today vs 20d5.48×
Avg vol (14d)1.57M
Avg vol (20d)1.49M
Avg $ vol (20d)65.04M
Market cap2.42B
RS Rating98 / 99
RS 3m (vs SPY)-26.46%
RS 6m (vs SPY)+117.38%
RS line new highNo
Trend template5/8
Technical rank61.9
1 week-13.10%
1 month-24.95%
3 months-21.97%
6 months+134.20%
1 year+180.49%
YTD+63.81%
P/E-12.14
P/B16.18
P/S—
P/FCF-13.54
EPS-3.46
Div yield—
ROE-133.23%
ROA-25.55%
Debt/Eq0.41
Current10.40
EV/EBITDA-13.70
Gross margin—
Net margin—
Rev growth—
EPS growth16.94%
Price target66.88
Target upside74.55%
Analyst ratingBuy
Institutional97.67%
Ent. value2.34B
Revenue3.56M
Net income-53.53M
Gross profit—
Free cash flow-178.4M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out63.07M
Employees221
ListedWed, Feb 5, 2014
Free float55.88M
Float %89.4%
Short interest9.87M
Days to cover9.4d
Short volume33.4%
Squeeze score75 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.22 vs −$0.81
Last surprise-50.6% miss
Setup gradeC
Conviction51 / 100
Pattern quality—
Tech rank61.9 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance51.34
Support42.36
Days since event—
Candle confirm—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in QURE
No recent disclosed trades by Congress in QURE. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in QURE · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Exercise | 21.08K | $409K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 9.2K | $409K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 4.28K | $195K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 7.6K | $349K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Stock Option (Right to Buy) · 2026-07-02 | Exercise | 21.08K | — | 2026-07-02 | 2026-07-07 |
Abi-Saab Walid Chief Medical Officer · Ordinary Shares · 2026-06-26 | Sell | 1.43K | $67K | 2026-06-26 | 2026-06-30 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Exercise | 4.66K | $148K | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Stock Option (Right to Buy) · 2026-06-18 | Exercise | 4.66K | — | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Sell | 4.66K | $233K | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Sell | 37.02K | $1.9M | 2026-06-18 | 2026-06-22 |
SEC filings
EDGAR filings in QURE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.